StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics, Inc. saw revenue fall 14.5% to $742.00K over the twelve months to Jun 30, 2026. Free cash flow was -$50.90M. At the latest close the market valued the company at $757.50K.

Revenue
$742.00K
-14.5% vs. a year earlier
Operating income
-$44.93M
TTM Q2 2026
Free cash flow
-$50.90M
TTM Q2 2026
EPS, diluted
-$3.78
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$757.50K
P/E ratio
–
Price to sales
1.02
Price to book
–
Dividend yield
–
Free cash flow yield
-6720.00%

Fundamentals

Revenue
$742.00K
Net income
-$70.86M
EPS, diluted
-$3.78
Free cash flow
-$50.90M
Book value per share
-$3.81
Diluted shares
30M

Trading

Previous close
$0.03
Open
$0.02
Day's range
$0.02 – $0.03
Volume
146,572
Average volume (20 days)
396,018

Market cap history

Month-end market cap since 2018, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodBTAIQS&P 500DifferenceBTAIQ per yearS&P 500 per year
1 month-56.9%+0.6%−57.5 pts
3 months-97.2%+3.4%−100.6 pts
Year to date-98.4%+13.3%−111.7 pts
1 year-98.9%+16.6%−115.5 pts
3 years-99.9%+86.4%−186.3 pts-91.6%+23.1%
5 years-100.0%+81.9%−181.8 pts-86.0%+12.7%

Ten years at a glance

Fiscal years 2016 to 2025 and trailing twelve months, USD

Revenue

$742.00K-14.5% YoY

Gross profit

$394.00K

Operating income

-$44.93M

Net income

-$70.86M

EPS, diluted

-$3.78

Free cash flow

-$50.90M
Reported periodTrailing twelve months

Press releases

Releases BioXcel Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About BioXcel Therapeutics

Pharmaceutical Preparations

BioXcel Therapeutics, Inc. is a biopharmaceutical company that develops medicines in neuroscience, alongside its wholly owned subsidiary OnkosXcel Therapeutics, which focuses on immuno-oncology. The company utilizes a proprietary artificial intelligence platform designed to identify new therapeutic indications from existing approved drugs or clinical candidates to treat disorders with unmet medical needs. Its commercialized product is IGALMI, a sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation linked to schizophrenia or bipolar I or II disorder in adults. Its clinical pipeline includes BXCL501 for acute agitation across neuropsychiatric conditions and BXCL701 for various aggressive tumors. Target customers encompass healthcare providers, hospitals, integrated delivery networks, and patients requiring agitation management.

Company profile, executives and history

BioXcel Therapeutics stock: common questions

What is BioXcel Therapeutics's stock price?

BTAIQ closed at $0.03 on Oct 19, 2026, down 13.49% on the day.

What is BioXcel Therapeutics's market cap?

BioXcel Therapeutics was worth $757.50K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is BTAIQ's P/E ratio?

BioXcel Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.78), so it has no meaningful P/E ratio.

How much revenue does BioXcel Therapeutics make?

BioXcel Therapeutics reported revenue of $742.00K for the twelve months to Jun 30, 2026, down 14.5% from a year earlier.

Does BioXcel Therapeutics pay a dividend?

No. BioXcel Therapeutics has not paid a cash dividend over the last twelve months.

How has BTAIQ stock performed over the past year?

Including dividends, BTAIQ returned -98.9% over the past year, against +16.6% for the S&P 500.

Who are BioXcel Therapeutics's competitors?

Companies most similar to BioXcel Therapeutics by business, industry and size include IGC, SPRB, VCNX, OVID, MNOV.

See a number that looks wrong?